GALT

Business Context and Reporting Period

Company: Galectin Therapeutics Inc. (GALT)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Galectin Therapeutics is a clinical-stage biopharmaceutical company developing therapies for fibrotic diseases and cancer by targeting galectin proteins. Its lead product candidate is belapectin, a galectin-3 inhibitor derived from plant-based materials, currently in development for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis and for immuno-oncology applications.

Key Financial Metrics

Debt and Liquidity: As of December 31, 2024, the company had $15.1 million in unrestricted cash. It maintains a $6.0 million line of credit with its Chairman, Richard E. Uihlein. In March 2025, a supplemental line of credit for an additional $5.0 million was secured. Total liabilities stood at $120.6 million, primarily driven by convertible notes and lines of credit related to the Chairman.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately $6.0 million (14.6%) year-over-year, driven by higher R&D expenses and increased interest expense.
• R&D Expense Growth: R&D expenses rose by $4.4 million (13.8%) to $36.6 million, primarily due to costs associated with the NAVIGATE clinical trial and increased contract manufacturing costs for belapectin.
• Cash Burn: Net cash used in operating activities increased by $8.8 million to $41.8 million, reflecting the acceleration of clinical trial activities.
• Interest Expense: Interest expense more than doubled to $5.5 million from $2.8 million, attributed to the amortization of debt discounts on convertible notes and lines of credit.

Guidance, Outlook, and Risks

Clinical Trial Results (NAVIGATE)

In December 2024, the company presented top-line results for the NAVIGATE Phase 2b/3 trial evaluating belapectin for the prevention of esophageal varices in NASH cirrhosis patients:

• Intent-to-Treat (ITT): The composite endpoint did not reach statistical significance, though the incidence of varices was reduced by 43.2% in the 2 mg/kg dose group vs. placebo.
• Per-Protocol Population (PPP): The incidence of varices was reduced by 49.3% (p < 0.05) in the 2 mg/kg dose group.
• U.S. Subgroup: In the U.S. cohort (n=186), the incidence of varices was significantly reduced by 68.1% (p=0.02).
• Safety: The safety profile remained highly encouraging with no drug-related serious adverse events reported.

Outlook and Liquidity

Management has expressed substantial doubt about the company's ability to continue as a going concern. The company believes its current cash and available credit lines ($11 million total) are sufficient to fund operations through August 2025. Additional financing will be required thereafter, which may involve equity or debt issuances that could result in dilution.

Risks and Contingencies

• Capital Needs: The company has no revenue and relies entirely on external financing. Failure to secure additional capital could force a curtailment of operations.
• Regulatory Uncertainty: While the NAVIGATE trial showed positive signals in specific subgroups, the primary composite endpoint was not met in the ITT population, creating uncertainty regarding future regulatory approval pathways.
• Vendor Dispute: The company is involved in a dispute with a contract vendor regarding clinical trial management services outside the U.S., where the vendor claims approximately $1 million more than the company's accrued estimate.

Key Facts for Investor Verification

• Runway: Verify the sufficiency of the $15.1 million cash balance and $11 million in credit lines to sustain operations through August 2025.
• NAVIGATE Trial Interpretation: Assess the regulatory implications of the failed primary composite endpoint in the ITT population versus the positive results in the Per-Protocol and U.S. subgroups.
• Related Party Financing: Review the terms of the convertible notes and lines of credit provided by Chairman Richard E. Uihlein, including conversion prices (floor of $3.00) and warrant issuances, which represent significant potential dilution.
• Going Concern Status: Confirm the company's plan to raise capital post-August 2025 and the likelihood of success given the mixed clinical trial results.
• Vendor Dispute: Monitor the resolution of the $1 million dispute with the clinical trial vendor to assess potential additional liabilities.